Donor-derived CD123-CD16 bispecific antibody-modified NK cells therapy(Chinese PLA General Hospital)

N/A

Report date: 2025/02/27 20:00:09

Base Information

Drug NameDonor-derived CD123-CD16 bispecific antibody-modified NK cells therapy(Chinese PLA General Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionAnti-CD123Natural killer cell replacementsLow affinity immunoglobulin gamma Fc region receptor III-A modulators
TargetsInterleukin-3 receptor subunit alphaLow affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPla General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPla General Hospital
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A